FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381617300> ?p ?o ?g. }

• W4381617300 endingPage "3269" @default.
• W4381617300 startingPage "3269" @default.
• W4381617300 abstract "Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into ‘suboptimal’ vs. ‘optimal’ locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan–Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio—HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in ‘suboptimal location’ presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed." @default.
• W4381617300 created "2023-06-23" @default.
• W4381617300 creator A5002264909 @default.
• W4381617300 creator A5004046885 @default.
• W4381617300 creator A5004565281 @default.
• W4381617300 creator A5010105487 @default.
• W4381617300 creator A5027396370 @default.
• W4381617300 creator A5027548324 @default.
• W4381617300 creator A5036257020 @default.
• W4381617300 creator A5038816002 @default.
• W4381617300 creator A5048248914 @default.
• W4381617300 creator A5053309637 @default.
• W4381617300 creator A5054517575 @default.
• W4381617300 creator A5057743208 @default.
• W4381617300 creator A5066144557 @default.
• W4381617300 creator A5067464504 @default.
• W4381617300 creator A5080019152 @default.
• W4381617300 creator A5080639399 @default.
• W4381617300 creator A5090708450 @default.
• W4381617300 date "2023-06-21" @default.
• W4381617300 modified "2023-10-17" @default.
• W4381617300 title "Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction" @default.
• W4381617300 cites W1984471249 @default.
• W4381617300 cites W2000681830 @default.
• W4381617300 cites W2020215421 @default.
• W4381617300 cites W2048402592 @default.
• W4381617300 cites W2069524705 @default.
• W4381617300 cites W2078114654 @default.
• W4381617300 cites W2083748784 @default.
• W4381617300 cites W2095440892 @default.
• W4381617300 cites W2096998881 @default.
• W4381617300 cites W2126049444 @default.
• W4381617300 cites W2135101558 @default.
• W4381617300 cites W2145125881 @default.
• W4381617300 cites W2146085139 @default.
• W4381617300 cites W2148383053 @default.
• W4381617300 cites W2163403599 @default.
• W4381617300 cites W2564125866 @default.
• W4381617300 cites W2582878252 @default.
• W4381617300 cites W2729904693 @default.
• W4381617300 cites W2741606776 @default.
• W4381617300 cites W2796067155 @default.
• W4381617300 cites W2899140013 @default.
• W4381617300 cites W2907812174 @default.
• W4381617300 cites W2964517531 @default.
• W4381617300 cites W2990602950 @default.
• W4381617300 cites W3083762969 @default.
• W4381617300 cites W3090413519 @default.
• W4381617300 cites W3103543294 @default.
• W4381617300 cites W3104744555 @default.
• W4381617300 cites W3133587281 @default.
• W4381617300 cites W3133992342 @default.
• W4381617300 cites W3165481767 @default.
• W4381617300 cites W3204060957 @default.
• W4381617300 cites W3213277274 @default.
• W4381617300 cites W3214030735 @default.
• W4381617300 cites W3214323987 @default.
• W4381617300 cites W4200158019 @default.
• W4381617300 cites W4200522816 @default.
• W4381617300 cites W4210839041 @default.
• W4381617300 cites W4213128706 @default.
• W4381617300 cites W4287542964 @default.
• W4381617300 cites W4294838953 @default.
• W4381617300 cites W4306173861 @default.
• W4381617300 cites W4377011124 @default.
• W4381617300 cites W4381283699 @default.
• W4381617300 doi "https://doi.org/10.3390/cancers15133269" @default.
• W4381617300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37444380" @default.
• W4381617300 hasPublicationYear "2023" @default.
• W4381617300 type Work @default.
• W4381617300 citedByCount "0" @default.
• W4381617300 crossrefType "journal-article" @default.
• W4381617300 hasAuthorship W4381617300A5002264909 @default.
• W4381617300 hasAuthorship W4381617300A5004046885 @default.
• W4381617300 hasAuthorship W4381617300A5004565281 @default.
• W4381617300 hasAuthorship W4381617300A5010105487 @default.
• W4381617300 hasAuthorship W4381617300A5027396370 @default.
• W4381617300 hasAuthorship W4381617300A5027548324 @default.
• W4381617300 hasAuthorship W4381617300A5036257020 @default.
• W4381617300 hasAuthorship W4381617300A5038816002 @default.
• W4381617300 hasAuthorship W4381617300A5048248914 @default.
• W4381617300 hasAuthorship W4381617300A5053309637 @default.
• W4381617300 hasAuthorship W4381617300A5054517575 @default.
• W4381617300 hasAuthorship W4381617300A5057743208 @default.
• W4381617300 hasAuthorship W4381617300A5066144557 @default.
• W4381617300 hasAuthorship W4381617300A5067464504 @default.
• W4381617300 hasAuthorship W4381617300A5080019152 @default.
• W4381617300 hasAuthorship W4381617300A5080639399 @default.
• W4381617300 hasAuthorship W4381617300A5090708450 @default.
• W4381617300 hasBestOaLocation W43816173001 @default.
• W4381617300 hasConcept C126322002 @default.
• W4381617300 hasConcept C137668524 @default.
• W4381617300 hasConcept C141071460 @default.
• W4381617300 hasConcept C142724271 @default.
• W4381617300 hasConcept C143998085 @default.
• W4381617300 hasConcept C207103383 @default.
• W4381617300 hasConcept C2776231280 @default.
• W4381617300 hasConcept C2778019345 @default.

• next